<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01290315</url>
  </required_header>
  <id_info>
    <org_study_id>1VIT08022</org_study_id>
    <nct_id>NCT01290315</nct_id>
  </id_info>
  <brief_title>Intravenous Ferric Carboxymaltose vs IV Iron Sucrose or IV Iron Dextran in Treating Iron Deficiency Anemia in Women</brief_title>
  <official_title>A Randomized, Controlled Study to Investigate the Safety and Oxidative Stress Potential of Intravenous Ferric Carboxymaltose (FCM) vs. IV Iron Sucrose or IV Iron Dextran in Treating Iron Deficiency Anemia in Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Luitpold Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Luitpold Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare safety and the oxidative stress potential of two
      doses of an investigational IV iron, ferric carboxymaltose (FCM), compared to an equal single
      dose of IV iron sucrose or IV iron dextran in the treatment of Iron Deficiency Anemia (IDA)
      in female subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a Phase 2a, open-label, multicenter, randomized study that compared the safety and
      oxidative stress potential of FCM vs. IV iron sucrose or IV iron dextran in female subjects
      with IDA. Subjects with a diagnosis of IDA who required iron supplementation met all
      inclusion and no exclusion criteria, and had given informed consent were randomized. The
      duration of the study for each subject was a maximum of 6 weeks.

      Eligible subjects were randomized in a 1:1 ratio to FCM (Group A) or IV iron sucrose or IV
      iron dextran (Group B).

      Group A subjects received a single undiluted dose of iron as FCM by a slow IV injection on
      Day 0. Cohort I received 500 mg and Cohort II received 750 mg. Group B subjects received a
      single dose of iron as IV iron sucrose or as IC iron dextran on Day 0. Cohort I receive 500
      mg iron sucrose and Cohort II received 750 mg iron dextran. Iron dextran administration was
      preceded by a 25 mg test dose 1 hour prior to infusion.

      All subjects had laboratory assessments at Baseline, 2 hours post-infusion, 24 hours
      post-infusion, Day 7 (drawn at the same time of day [within 4 hours] as the 24-hour visit),
      and Day 30 (drawn at the same time of day [within 4 hours] as the the 24-hour visit). On Days
      7 and 30, the safety evalutation for all subjects included treatment-emergent adverse event
      reporting, concomitant medication review, physical examination including vital signs, and
      laboratory assessments. Any subject who withdrew from the study received a follow-up phone
      call 30 days after they received study drug.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 2009</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes From Baseline in Markers of Oxidative Stress (Carbonyl and 8-isoprostane)</measure>
    <time_frame>Change from Baseline to Day 30</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes From Baseline in Markers of Oxidative Stress (Carbonyl and 8-isoprostane)</measure>
    <time_frame>Change from baseline to 2 hours post end IV infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes From Baseline in Markers of Oxidative Stress (Carbonyl and 8-isoprostane)</measure>
    <time_frame>Change from baseline to 24 hours post end IV infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes From Baseline in Markers of Oxidative Stress (Carbonyl and 8-isoprostane)</measure>
    <time_frame>Change from baseline to Day 7 post end IV infusion</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Iron Deficiency Anemia</condition>
  <arm_group>
    <arm_group_label>Ferric Carboxymaltose (FCM)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous iron</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Iron Sucrose / Iron Dextran</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravenous iron</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ferric Carboxymaltose (FCM)</intervention_name>
    <description>One 500 mg dose at 100 mg/minute (Cohort I) or 750 mg dose at 100 mg/minute (Cohort II)</description>
    <arm_group_label>Ferric Carboxymaltose (FCM)</arm_group_label>
    <other_name>Injectafer</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iron Sucrose / Iron Dextran</intervention_name>
    <description>One 500 mg dose of IV iron sucrose administered over 4 hours (Cohort I), or a 750 mg dose of IV iron dextran administered as a 25 mg test dose over 5 minutes followed by a 725 mg dose over 3 hours if no adverse reaction to test dose is observed after 60 minutes (Cohort II)</description>
    <arm_group_label>Iron Sucrose / Iron Dextran</arm_group_label>
    <other_name>Venofer, Dexferrum</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female subjects 18-50 years of age and able to give informed consent.

          -  If post-partum, at least 10 days post delivery at Day 0.

          -  Screening Visit local laboratory Hgb &lt; or = to 10 g/dL or &lt; or = to 12 g/dL with
             symptoms (dizziness and/or fatigue).

          -  Screening Visit ferritin &lt; or = to 100 ng/mL or &lt; or = to 300 when TSAT is &lt; or = to
             30%.

          -  Documented unsatisfactory response or intolerance to oral iron.

        Exclusion Criteria:

          -  Previous participation in a ferric carboxymaltose (FCM) clinical trial.

          -  Known hypersensitivity reaction to any component of ferric carboxymaltose, Venofer, or
             Dexferrum.

          -  History of drug allergy or any history of rheumatoid arthritis or other autoimmune
             diseases.

          -  Current anemia not attributed to iron deficiency.

          -  During the 10 day period prior to screening has been treated with antibiotics.

          -  During the 30 day period prior to screening or during the study period has or will be
             treated with erythropoiesis stimulating agents.

          -  Active malignancy within 5 years. Basal or squamous cell skin cancer is not
             exclusionary.

          -  During the 30 day period prior to screening or during the study period has or will
             require a surgical procedure that necessitates general anesthesia.

          -  Current (acute or chronic) infection other than viral upper respiratory tract
             infection.

          -  AST or ALT at screening greater than 1.5 times the upper limit of normal.

          -  Known positive hepatitis B with evidence of active hepatitis.

          -  Known positive HIV-1/HIV-2 antibodies (anti-HIV).

          -  Patient has an active diagnosis of asthma and is currently using an anti- asthmatic
             therapy.

          -  Received an investigational drug within 30 days of screening.

          -  Alcohol or drug abuse within the past 6 months.

          -  Hemochromatosis or other iron storage disorders.

          -  Systolic blood pressure &gt; or = to 180 or &lt; 80 mmHg or diastolic blood pressure &gt; or =
             to 100 or &lt; 40 mmHg at screening or Day 0.

          -  Chronic kidney disease.

          -  Chronic inflammatory condition including but not limited to Lupus and Rheumatoid
             Arthritis.

          -  Pre-term delivery &lt; 32 weeks.

          -  Emergent C-section delivery.

          -  Significant cardiovascular disease, including but not limited to myocardial infarction
             or unstable angina within 6 months prior to study inclusion or current history of NYHA
             Class III or IV congestive heart failure.

          -  Any other laboratory abnormality, medical condition or psychiatric disorder which in
             the opinion of the investigator puts the subject's disease management at risk or may
             result in the subject being unable to comply with study requirements.

          -  Night shift workers.

          -  Breastfeeding planned on or after Day 0.

          -  Pregnant or sexually-active female subjects who are of childbearing potential and who
             don't use an acceptable form of contraception.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Linda M Mundy, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Luitpold Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Luitpold Pharmaceuticals, Inc.</name>
      <address>
        <city>Norristown</city>
        <state>Pennsylvania</state>
        <zip>19403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 10, 2010</study_first_submitted>
  <study_first_submitted_qc>February 3, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 7, 2011</study_first_posted>
  <results_first_submitted>June 11, 2015</results_first_submitted>
  <results_first_submitted_qc>February 2, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">February 8, 2018</results_first_posted>
  <last_update_submitted>February 2, 2018</last_update_submitted>
  <last_update_submitted_qc>February 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Anemia, Iron-Deficiency</mesh_term>
    <mesh_term>Deficiency Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Iron</mesh_term>
    <mesh_term>Ferric oxide, saccharated</mesh_term>
    <mesh_term>Ferric Compounds</mesh_term>
    <mesh_term>Iron-Dextran Complex</mesh_term>
    <mesh_term>Dextrans</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Hospitals and Medical Clinics. December 6, 2010 through October 13, 2012.</recruitment_details>
      <pre_assignment_details>Discontinuation prior to dosing included lost to follow-up, subject request, and selection criteria/study compliance. A total of 19 subjects were excluded from the population of subjects evaluated for efficacy and safety-5 randomized to FCM 500mg, 2 randomized to FCM 750mg, 6 randomized to iron sucrose 500mg, and 6 randomized to iron dextran 750mg.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Ferric Carboxymaltose (FCM) Cohort I</title>
          <description>Intravenous iron
Ferric Carboxymaltose (FCM): One 500 mg dose at 100 mg/minute (Cohort I)</description>
        </group>
        <group group_id="P2">
          <title>Iron Sucrose Cohort I</title>
          <description>Intravenous iron
Iron Sucrose: One 500 mg dose of IV iron sucrose administered over 4 hours (Cohort I)</description>
        </group>
        <group group_id="P3">
          <title>Ferric Carboxymaltose (FCM) Cohort II</title>
          <description>Intravenous iron
Ferric Carboxymaltose (FCM): One 750 mg dose at 100 mg/minute (Cohort II)</description>
        </group>
        <group group_id="P4">
          <title>Iron Dextran Cohort II</title>
          <description>Intravenous iron
Iron Dextran: One 750 mg dose of IV iron dextran administered as a 25 mg test dose over 5 minutes followed by a 725 mg dose over 3 hours if no adverse reaction to test dose is observed after 60 minutes (Cohort II)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Selection criteria/compliance</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ferric Carboxymaltose (FCM) Cohort I</title>
          <description>Intravenous iron
Ferric Carboxymaltose (FCM): One 500 mg dose at 100 mg/minute (Cohort I)</description>
        </group>
        <group group_id="B2">
          <title>Iron Sucrose Cohort I</title>
          <description>Intravenous iron
Iron Sucrose: One 500 mg dose of IV iron sucrose administered over 4 hours (Cohort I)</description>
        </group>
        <group group_id="B3">
          <title>Ferric Carboxymaltose (FCM) Cohort II</title>
          <description>Intravenous iron
Ferric Carboxymaltose (FCM): One 750 mg dose at 100 mg/minute (Cohort II)</description>
        </group>
        <group group_id="B4">
          <title>Iron Dextran Cohort II</title>
          <description>Intravenous iron
Iron Dextran: One 750 mg dose of IV iron dextran administered as a 25 mg test dose over 5 minutes followed by a 725 mg dose over 3 hours if no adverse reaction to test dose is observed after 60 minutes (Cohort II)</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="10"/>
            <count group_id="B4" value="13"/>
            <count group_id="B5" value="49"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="49"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.1" spread="7.66"/>
                    <measurement group_id="B2" value="29.6" spread="9.93"/>
                    <measurement group_id="B3" value="39.2" spread="7.97"/>
                    <measurement group_id="B4" value="39.2" spread="9.21"/>
                    <measurement group_id="B5" value="34.8" spread="9.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="49"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Changes From Baseline in Markers of Oxidative Stress (Carbonyl and 8-isoprostane)</title>
        <time_frame>Change from Baseline to Day 30</time_frame>
        <population>Only subjects with both a Baseline and at least one post-Baseline value are included.</population>
        <group_list>
          <group group_id="O1">
            <title>Ferric Carboxymaltose (FCM) Cohort I</title>
            <description>Intravenous iron
Ferric Carboxymaltose (FCM): One 500 mg dose at 100 mg/minute (Cohort I)</description>
          </group>
          <group group_id="O2">
            <title>Iron Sucrose Cohort I</title>
            <description>Intravenous iron
Iron Sucrose: One 500 mg dose of IV iron sucrose administered over 4 hours (Cohort I)</description>
          </group>
          <group group_id="O3">
            <title>Ferric Carboxymaltose (FCM) Cohort II</title>
            <description>Intravenous iron
Ferric Carboxymaltose (FCM): One 750 mg dose at 100 mg/minute (Cohort II)</description>
          </group>
          <group group_id="O4">
            <title>Iron Dextran Cohort II</title>
            <description>Intravenous iron
Iron Dextran: One 750 mg dose of IV iron dextran administered as a 25 mg test dose over 5 minutes followed by a 725 mg dose over 3 hours if no adverse reaction to test dose is observed after 60 minutes (Cohort II)</description>
          </group>
        </group_list>
        <measure>
          <title>Changes From Baseline in Markers of Oxidative Stress (Carbonyl and 8-isoprostane)</title>
          <population>Only subjects with both a Baseline and at least one post-Baseline value are included.</population>
          <units>mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Carbonyl</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.90" spread="52.55"/>
                    <measurement group_id="O2" value="-1.06" spread="38.722"/>
                    <measurement group_id="O3" value="-12.37" spread="32.91"/>
                    <measurement group_id="O4" value="-11.14" spread="48.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8-isoprostane</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="141.46" spread="892.16"/>
                    <measurement group_id="O2" value="-369.50" spread="957.06"/>
                    <measurement group_id="O3" value="8.83" spread="81.20"/>
                    <measurement group_id="O4" value="32.28" spread="233.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Changes From Baseline in Markers of Oxidative Stress (Carbonyl and 8-isoprostane)</title>
        <time_frame>Change from baseline to 2 hours post end IV infusion</time_frame>
        <population>Only subjects with both a baseline and at least one post baseline value are included.</population>
        <group_list>
          <group group_id="O1">
            <title>Ferric Carboxymaltose (FCM) Cohort I</title>
            <description>Intravenous iron
Ferric Carboxymaltose (FCM): One 500 mg dose at 100 mg/minute (Cohort I)</description>
          </group>
          <group group_id="O2">
            <title>Iron Sucrose Cohort I</title>
            <description>Intravenous iron
Iron Sucrose: One 500 mg dose of IV iron sucrose administered over 4 hours (Cohort I)</description>
          </group>
          <group group_id="O3">
            <title>Ferric Carboxymaltose (FCM) Cohort II</title>
            <description>Intravenous iron
Ferric Carboxymaltose (FCM): One 750mg dose at 100 mg/minute (Cohort II)</description>
          </group>
          <group group_id="O4">
            <title>Iron Dextran Cohort II</title>
            <description>Intravenous iron
Iron Dextran: One 750 mg dose of IV iron dextran administered as a 25 mg test dose over 5 minutes followed by a 725 mg dose over 3 hours if no adverse reaction to test dose is observed after 60 minutes (Cohort II)</description>
          </group>
        </group_list>
        <measure>
          <title>Changes From Baseline in Markers of Oxidative Stress (Carbonyl and 8-isoprostane)</title>
          <population>Only subjects with both a baseline and at least one post baseline value are included.</population>
          <units>mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Carbonyl</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.07" spread="38.21"/>
                    <measurement group_id="O2" value="6.05" spread="24.69"/>
                    <measurement group_id="O3" value="-8.66" spread="43.15"/>
                    <measurement group_id="O4" value="-5.98" spread="23.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8-isoprostane</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="151.59" spread="833.75"/>
                    <measurement group_id="O2" value="-420.02" spread="803.52"/>
                    <measurement group_id="O3" value="-2.64" spread="30.44"/>
                    <measurement group_id="O4" value="-5.92" spread="216.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Changes From Baseline in Markers of Oxidative Stress (Carbonyl and 8-isoprostane)</title>
        <time_frame>Change from baseline to 24 hours post end IV infusion</time_frame>
        <population>Only subjects with both a baseline and at least one post baseline value are included.</population>
        <group_list>
          <group group_id="O1">
            <title>Ferric Carboxymaltose (FCM) Cohort I</title>
            <description>Intravenous iron
Ferric Carboxymaltose (FCM): One 500 mg dose at 100 mg/minute (Cohort I)</description>
          </group>
          <group group_id="O2">
            <title>Iron Sucrose Cohort I</title>
            <description>Intravenous iron
Iron Sucrose: One 500 mg dose of IV iron sucrose administered over 4 hours (Cohort I)</description>
          </group>
          <group group_id="O3">
            <title>Ferric Carboxymaltose (FCM) Cohort II</title>
            <description>Intravenous iron
Ferric Carboxymaltose (FCM): One 750 mg dose at 100 mg/minute (Cohort II)</description>
          </group>
          <group group_id="O4">
            <title>Iron Dextran Cohort II</title>
            <description>Intravenous iron
Iron Dextran: One 750 mg dose of IV iron dextran administered as a 25 mg test dose over 5 minutes followed by a 725 mg dose over 3 hours if no adverse reaction to test dose is observed after 60 minutes (Cohort II)</description>
          </group>
        </group_list>
        <measure>
          <title>Changes From Baseline in Markers of Oxidative Stress (Carbonyl and 8-isoprostane)</title>
          <population>Only subjects with both a baseline and at least one post baseline value are included.</population>
          <units>mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Carbonyl</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.63" spread="23.24"/>
                    <measurement group_id="O2" value="-6.92" spread="21.49"/>
                    <measurement group_id="O3" value="8.94" spread="87.05"/>
                    <measurement group_id="O4" value="-11.57" spread="40.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8-isoprostane</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="198.67" spread="864.29"/>
                    <measurement group_id="O2" value="119.26" spread="575.29"/>
                    <measurement group_id="O3" value="-23.96" spread="60.01"/>
                    <measurement group_id="O4" value="38.02" spread="190.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Changes From Baseline in Markers of Oxidative Stress (Carbonyl and 8-isoprostane)</title>
        <time_frame>Change from baseline to Day 7 post end IV infusion</time_frame>
        <population>Only subjects with both a baseline and at least one post baseline value are included.</population>
        <group_list>
          <group group_id="O1">
            <title>Ferric Carboxymaltose (FCM) Cohort I</title>
            <description>Intravenous iron
Ferric Carboxymaltose (FCM): One 500 mg dose at 100 mg/minute (Cohort I)</description>
          </group>
          <group group_id="O2">
            <title>Iron Sucrose Cohort I</title>
            <description>Intravenous iron
Iron Sucrose: One 500 mg dose of IV iron sucrose administered over 4 hours (Cohort I)</description>
          </group>
          <group group_id="O3">
            <title>Ferric Carboxymaltose (FCM) Cohort II</title>
            <description>Intravenous iron
Ferric Carboxymaltose (FCM): One 750 mg dose at 100 mg/minute (Cohort II)</description>
          </group>
          <group group_id="O4">
            <title>Iron Dextran Cohort II</title>
            <description>Intravenous iron
Iron Dextran: One 750 mg dose of IV iron dextran administered as a 25 mg test dose over 5 minutes followed by a 725 mg dose over 3 hours if no adverse reaction to test dose is observed after 60 minutes (Cohort II)</description>
          </group>
        </group_list>
        <measure>
          <title>Changes From Baseline in Markers of Oxidative Stress (Carbonyl and 8-isoprostane)</title>
          <population>Only subjects with both a baseline and at least one post baseline value are included.</population>
          <units>mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Carbonyl</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.69" spread="36.43"/>
                    <measurement group_id="O2" value="-24.03" spread="65.55"/>
                    <measurement group_id="O3" value="-18.20" spread="45.92"/>
                    <measurement group_id="O4" value="-12.10" spread="54.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8-isoprostane</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="263.52" spread="896.57"/>
                    <measurement group_id="O2" value="-417.89" spread="1030.83"/>
                    <measurement group_id="O3" value="-29.35" spread="56.88"/>
                    <measurement group_id="O4" value="-58.04" spread="159.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year and 10 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Ferric Carboxymaltose (FCM)</title>
          <description>Intravenous iron
Ferric Carboxymaltose (FCM): One 500 mg dose at 100 mg/minute (Cohort I) or 750 mg dose at 100 mg/minute (Cohort II)</description>
        </group>
        <group group_id="E2">
          <title>Iron Sucrose or Iron Dextran</title>
          <description>Intravenous iron
Iron Sucrose / Iron Dextran: One 500 mg dose of IV iron sucrose administered over 4 hours (Cohort I), or a 750 mg dose of IV iron dextran administered as a 25 mg test dose over 5 minutes followed by a 725 mg dose over 3 hours if no adverse reaction to test dose is observed after 60 minutes (Cohort II)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic Reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site bruising</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Angelia Butcher</name_or_title>
      <organization>Luitpold Pharmaceuticals, Inc.</organization>
      <phone>610-650-4200 ext 811</phone>
      <email>abutcher@luitpold.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

